This trial is testing a new drug, IMU-838, to see if it's effective and safe for people with progressive multiple sclerosis.
2 Primary · 1 Secondary · Reporting Duration: 24 weeks
Experimental Treatment
Non-Treatment Group
450 Total Participants · 2 Treatment Groups
Primary Treatment: IMU-838 · Has Placebo Group · Phase 2
Age 18 - 65 · All Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:18 - 65 | 100.0% |
Los Angeles County Harbor UCLA, Medical Center and Lundquist Institute | 50.0% |
Montreal Neurological Inst. | 50.0% |
Met criteria | 50.0% |
Did not meet criteria | 50.0% |
California | 100.0% |